MedTrace Logo

Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer

NCT00433563 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 547

Last updated 2022-09-08

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which schedule of radiation therapy is more effective when given together with chemotherapy in treating small cell lung cancer.

PURPOSE: This randomized phase III trial is studying two different schedules of radiation therapy to compare how well they work when given together with cisplatin and etoposide in treating patients with limited stage small cell lung cancer.

Conditions

Interventions

RADIATION

Once daily radiotherapy

Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy

RADIATION

Twice daily radiotherapy

Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • NCIC Clinical Trials Group

    collaborator NETWORK

  • European Organisation for Research and Treatment of Cancer - EORTC

    collaborator NETWORK

  • Spanish Lung Cancer Group

    collaborator OTHER

  • Groupe Francais De Pneumo-Cancerologie

    collaborator OTHER

  • Intergroupe Francophone de Cancerologie Thoracique

    collaborator OTHER

  • The Christie NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Corinne Faivre-Finn, MD · The Christie NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2016-02-29
Completion
2019-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00433563 on ClinicalTrials.gov